Q2 2026 saw 15.2% revenue growth, improved net loss, and positive adjusted EBITDA. Guidance for 2026 revenue was raised to $231–$233 million, with strong U.S. and international performance, favorable reimbursement, and new product launches expected to drive further growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.